AIs improve outcomes in the adjuvant treatment of postmenopausal women with hormone receptor positive (HR+) BC compared with tamoxifen decreasing the risk of recurrence (20–36%) and decreasing 10-year breast cancer mortality (12.1% vs. 14.2% RR 0·85, 0·75–0·96; 2p = 0·009) [4]. The gene discussed is NR4A1; the disease is breast cancer.